药明巨诺百万一针的CAR-T药物有望进入商保目录

Core Viewpoint - WuXi AppTec's CAR-T cell therapy, Rukiyou Lunsai injection, is making significant progress in negotiations to be included in the commercial health insurance innovative drug directory, which is expected to reduce the financial burden on patients and benefit more individuals [1] Company Summary - WuXi AppTec's Rukiyou Lunsai injection is the first domestically approved Class 1 CAR-T therapy in China [1] - The pricing for the therapy post-launch is set at 1.29 million yuan per injection [1]